36 / 59
1. Do asymptomatic and M0 patients need to be treated?
2. Is MFS an adequate endpoint?
3. Do clinical benefit balance side effects? Do prolonged exposure to
drugs provoke safety concerns?
4. Do benefit justify costs?
PIVOTAL TRIALS IN M0 CRPC